Medicash, a leading provider of health cash plans in the UK, is proud to announce a significant milestone in its partnership with SkinVision, with the app successfully identifying its 1,000th clinically validated case of skin cancer among Medicash policyholders since the service launched in 2020. This achievement underscores Medicash’s commitment to enhancing the wellbeing of its members through early detection, proactive healthcare, and access to digital innovations.
Since introducing SkinVision to policyholders four years ago, Medicash has empowered thousands of individuals with convenient, self-directed access to skin health assessments. The SkinVision app allows users to monitor suspicious moles and skin lesions and receive a clinically backed risk assessment. By flagging potential issues early, the app has proven invaluable in enabling early intervention for policyholders, directly contributing to faster diagnoses and improved health outcomes.
“This milestone reflects the effectiveness of our partnership with SkinVision in making skin health assessment more accessible and potentially life-saving,” said Sue Weir, Medicash chief executive. “With skin cancer rates on the rise, particularly in the UK, it is essential that our policyholders have the tools to identify potential issues as early as possible. Our collaboration with SkinVision is a powerful example of how technology can improve wellbeing outcomes, ultimately transforming lives and strengthening healthcare support.”
One policyholder who has benefited from SkinVision is Melanie, 45, who had a mole on her shin that caught her eye. When it started to change shape and develop an irregular edge she decided to take action.
“My employer Fintel provides a health cash plan with Medicash which includes free access to SkinVision. When I took a picture of the mole with the SkinVision app it came back saying it looks suspicious and I should get it looked at. After the advice I sent the pictures to my GP, and they referred me to a dermatologist straight away. The dermatologist initially thought it would be an in-situ melanoma, but it turned out to have moved into the entire epidermis, so it was stage 1.
“After my experience with skin cancer, I found out that a friends’ mum sadly died of melanoma, which had a big impact on me. So, I told everybody on Facebook about my story and encouraged others to get their moles checked. You just don’t expect to ever get such a diagnosis yourself; it was really scary especially with two children. So, today I am sharing my story because I want to encourage other people to get their skin checked. Not only moles but everything, lumps, bumps, anything.”
The success of the Medicash-SkinVision partnership is also highlighted by the platform’s ease of use and high clinical accuracy. By uploading images through the app, policyholders receive a risk assessment within minutes, with follow-up clinical validation via a team of specialist dermatologists ensuring a high level of reliability. Since 2020, thousands of Medicash members have utilised SkinVision as a convenient tool for ongoing skin health management, often from the comfort of their own homes.
This achievement also aligns with Medicash’s broader commitment to harnessing digital health innovations that support preventative care and raise awareness around skin health. The ongoing partnership with SkinVision is part of Medicash’s mission to provide cost-effective and user-friendly wellbeing solutions, equipping policyholders with accessible options to proactively manage their health.
